Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 241

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

From Low to No O2-Dependent Hypoxia Photodynamic Therapy (hPDT): A New Perspective

Li, Mingle, Xu, Yunjie, Peng, Xiaojun, Kim, Jong Seung·2022·Accounts of Chemical Research

Abstract

Conspectus The advent of photochemical techniques has revolutionized the landscape of biology and medical sciences. Especially appealing in this context is photodynamic therapy (PDT), which is a photon-initiated treatment modality that uses cytotoxic reactive oxygen species (ROS) to kill malignant cells. In the past decade, PDT has risen to the forefront of cancer therapy. Its optical control enables noninvasive and spatiotemporal manipulation of the treatment process, and its photoactive nature allows unique patterns to avoid drug resistance to conventional chemotherapeutics. However, despite the impressive advances in this field, achieving widespread clinical adoption of PDT remains difficult. A major concern is that in the hostile tumor microenvironment, tumor cells are hypoxic, which hinders ROS generation during PDT action. To overcome this “Achilles’ heel”, current strategies focus primarily on the improvement of the intratumoral O 2 perfusion, while clinical trials suggest that O 2 enrichment may promote cancer cell proliferation and metastasis, thereby making FDA approval and clinical transformation of these paradigms challenging. In an effort to improve hypoxia photodynamic therapy (hPDT) in the clinic, we have explored “low to no O 2 -dependent” photochemical approaches over the years to combat hypoxia-induced resistance. In this Account, we present our contributions to this theme during the past 5 years, beginning with low O 2 -dependent approaches (e.g., type I superoxide radical (O 2 •– ) generator, photodynamic O 2 -economizer, mitochondrial respiration inhibition, cellular self-protective pathway modulation, etc.) and progressing to O 2 -independent strategies (e.g., autoadaptive PDT/PTT complementary therapy, O 2 -independent artificial photoredox catalysis in cells). These studies have attracted tremendous attention. Particularly in the pioneering work of 2018, we presented the first demonstration that the O 2 •– -mediated partial O 2 -recyclability mechanism can overcome PDT resistance ( J. Am. Chem. Soc. 2018, 140, 14851−14859). This launched an era of renewed interest in type I PDT, resulting in a plethora of new O 2 •– photogenerators developed by many groups around the world. Moreover, with the discovery of O 2 -independent photoredox reactions in living cells, artificial photoredox catalysis has emerged as a new field connecting photochemistry and biomedicine, stimulating the development of next-generation phototherapeutic tools ( J. Am. Chem. Soc. 2022, 144, 163−173). Our recent work also disclosed that “photoredox catalysis in cells” might be a general mechanism of action of PDT ( Proc. Natl. Acad. Sci. U.S.A. 2022, 119, e2210504119 ). These emergent concepts, molecular designs, photochemical mechanisms, and applications in cancer diagnosis and therapeutics, as well as pros and cons, are discussed in depth in this Account. It is expected that our contributions to date will be of general use to researchers and inspire future efforts to identify more promising hPDT approaches that better meet the clinical needs of cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.accounts.2c00531

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 241

Metadata

Authors
Li, M., Xu, Y., Peng, X., & Kim, J. S.
Venue
Accounts of Chemical Research
Published
2022-11-02
Volume
55
Issue
22
Pages
3253-3264
ISSN
  • 0001-4842 (ISSN-L)
  • 1520-4898
OpenAlex
W4308054433
Cited by
241
References
3
FWCI
24.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.